This Is MS Multiple Sclerosis Community: Knowledge & Support

I was considering ccvsi. I've got a request in at a vascular doctors office since I've been denied a second round of campath due to low lymphocyte counts that didn't rebound in time. After making the ccvsi call and gearing up to pursue it I got a call from my campath study neurologists office. Genzyme is making a tweak to the study protocol. Now at month 14 after the first dose if you didn't qualify ...

a one-two punch.....time will tell

Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme's Phase 2 Trial Remain Free of Clinically-Active Disease

Apr 14, 2010 (BUSINESS WIRE) -- Genzyme Corporation /quotes/comstock/15*!genz/quotes/nls/genz (GENZ 53.58, -0.06, -0.11%) today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The ...

Significant percentage of MS patients receiving Alemtuzumab in Genzyme's phase 2 trial remain free of clinically-active disease - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307

Hello everybody
I'm writing here in behalf of my friend from Poland. He's in his 20's, asked me for help to translate. He's looking for anybody who already took second dose (second part?) of 12mg Campath. He would like to know is there any side effects. Please share your opinions. It's really tough to get any info at Polish discussion forums, that's why he decided to ask for info here. Thank you for any help.

My study is Care MS 1. This is Month 24. entering into the extension phase and just learned I received the 25mg dose both times. My MRI showed no new changes. My blood is stable: lymphs are low but within normal parameters. I didn't ask @ the levels on the CD 54+ (or whatever..they test a few and i don't have that part memorized-if u rly want to know how low they go w/ campath, ...

A good summary of the Campath research to date, that includes statistics for the early trials of the drug between 1991 and 2002 (along with the widely published Phase II trial results). The pdf linked below is much easier to read!

Yannis


<shortened url>


Spotlight on Alemtuzumab


Summary
Alemtuzumab, formally known as Campath-1H, is a humanized monoclonal antibody directed against CD52, a protein on the surface of lymphocytes and monocytes with unknown function. A single ...

Dear all,

There are a few Alemtuzumab (Campath) abstracts being presented at the AAN conference in April.

As someone who has had their two infusions - the last being 27 months ago, it's quite comforting that the treatment effect seems to hold good for the majority of patient for at least four years after treatment.

http://www.abstracts2view.com/aan/view. ... 0L_P04.213

I now have an annual MRI and a six-monthly check-up. My ...

Hi,

My MS has gradually worsened (walking more unstable) over a year, and my neuro suggested I look at Novantrone as an option -- see ehat 3 doses woul;d do etc.

I was wondering though, if I went for this option would it complicate using Campath -- or Revimmune -- in the future? Was thinking in terms of supressed immunity with a chemo drug and then problems using a monoclonal antibody.

Any input welcome! Also ...

Hi

Any of you guys know when Campath is likely to become a licenced/approved treatment in the UK and the US?

Have been reading different dates -- 2010, 2011, 2012 and so on.

Thanks

Camilla